Genfit (OTCMKTS:GNFTF – Get Free Report) is expected to be issuing its resultson Tuesday, September 29th. Analysts expect the company to post earnings of ($0.1827) per share and revenue of $34.8330 million for the quarter.
Genfit Stock Performance
GNFTF stock opened at $15.75 on Friday. The company has a 50 day simple moving average of $15.77 and a 200 day simple moving average of $12.22. Genfit has a 1 year low of $4.14 and a 1 year high of $16.50.
About Genfit
Genfit SA is a France-based biopharmaceutical company focused on developing medicines and diagnostic solutions for metabolic, liver and rare diseases. The company’s research programs target conditions with significant unmet medical needs, including metabolic dysfunction-associated steatohepatitis (MASH), primary biliary cholangitis and other progressive liver disorders.
Genfit’s pipeline has included investigational therapies designed to address liver inflammation, fibrosis and related metabolic complications.
Recommended Stories
- Five stocks we like better than Genfit
- 3 Defense Stocks Riding Nuclear, Missile, and Aerospace Demand
- SoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement
- These 3 Overlooked Stocks Have Big Money Behind Them
- Darden Restaurants Serves Up Fresh Catalysts for a Stock Price Rally
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.
